Cyotomedical therapy for insulinopenic diabetes using microencapsulated pancreatic β cell lines

Suzuki, Ryo; Okada, Naoki; Miyamoto, Hajime; Yoshioka, Tatsunobu; Sakamoto, K.; Oka, Hiroaki; Tsutsumi, Yasuo; Nakagawa, Shinsaku; Miyazaki, Jun‐ichi; Mayumi, Tadanori

doi:10.1016/s0024-3205(02)01724-1

Cited by 20 publications

(11 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Survival of grafted cells following transplantation into the cochlea is a major issue and cells may require a protective matrix, such as those used to protect islet or ␤ -cell grafts from the immune system for insulin production in diabetes mellitus [Suzuki et al, 2002]. Additionally, there needs to be a method of controlling where transplanted cells integrate, as maximum benefit would only be achieved if the cells migrated to damaged regions of the cochlea.…”

Section: Slow-release Polymers and Hydrogelsmentioning

confidence: 99%

Inner Ear Therapy for Neural Preservation

2006

View full text Add to dashboard Cite

A gradual loss of auditory neurons often occurs following sensorineural hearing loss. Since the cochlear implant must stimulate the remaining auditory neuron population, it would be beneficial to preserve as many auditory neurons as possible. Neurotrophic factors protect auditory neurons from degradation after sensorineural hearing loss in experimental animals, but have not yet been translated into the clinical setting. Current experimental and clinical techniques for drug delivery to the inner ear are examined in this review, covering the routes for drug delivery to the cochlea and the delivery systems used to introduce them. Duration of treatment, drug diffusion, effectiveness and safety are discussed with references to how they may be translated to the implementation of neurotrophic factor treatment for neural preservation.

show abstract

Section: Slow-release Polymers and Hydrogelsmentioning

confidence: 99%

Inner Ear Therapy for Neural Preservation

2006

View full text Add to dashboard Cite

show abstract

“…4,5 The biocompatibility of alginate has also enabled its use in clinical trials as a cell delivery vehicle for bone formation 6 and diabetes therapy. 7,8 The most common realization of alginate scaffolds is through ionic crosslinking with multivalent cations, most often calcium. 1,[9][10][11] Ionic crosslinking offers control of material properties through the concentration of calcium and alginate as well as the alginate molecular weight, and high process viabilities have been demonstrated in many studies.…”

Section: Introductionmentioning

confidence: 99%

Methods for Photocrosslinking Alginate Hydrogel Scaffolds with High Cell Viability

Rouillard

Berglund²,

Lee³

et al. 2011

Tissue Engineering Part C: Methods

186

183

View full text Add to dashboard Cite

Methods for seeding high-viability (>85%) three-dimensional (3D) alginate-chondrocyte hydrogel scaffolds are presented that employ photocrosslinking of methacrylate-modified alginate with the photoinitiator VA-086. Comparison with results from several other photoinitiators, including Irgacure 2959, highlights the role of solvent, ultraviolet exposure, and photoinitiator cytotoxicity on process viability of bovine chondrocytes in two-dimensional culture. The radicals generated from VA-086 photodissociation are shown to be noncytotoxic at w/v concentrations up to 1.5%, enabling photocrosslinking without significant cell death. The applicability of these photoinitiators for generating 3D tissue-engineered constructs is evaluated by measuring cell viability in 3D constructs with aggregate moduli in the 10-20 kPa range. Hydrogels with encapsulated bovine chondrocytes were constructed with >85% viability using VA-086. While the commonly used Irgacure 2959 is noncytotoxic in its native state and crosslinks the alginate at weight fractions much lower than VA-086, the cytotoxicity of IRG2959's photogenerated radical leads to viabilities below 70% in the conditions tested.

show abstract

“…Alginate microcapsules coated with a permselective poly‐ L ‐ornithine (PLO) layer have been investigated for islet cell encapsulation 5, 8. Alginate is composed of (1‐4)‐linked β‐ D ‐mannuronic acid (M‐units) and α‐ L ‐guluronic acid (G‐units) monomers and is a biocompatible material that has been used for a wide range of biomedical applications, including cell encapsulation and protein delivery 9–12.…”

Section: Introductionmentioning

confidence: 99%

Synthesis of multilayered alginate microcapsules for the sustained release of fibroblast growth factor‐1

Khanna

Moya

Opara

et al. 2010

J Biomedical Materials Res

View full text Add to dashboard Cite

Alginate microcapsules coated with a permselective poly-L-ornithine (PLO) membrane have been investigated for the encapsulation and transplantation of islets as a treatment for type 1 diabetes. The therapeutic potential of this approach could be improved through local stimulation of microvascular networks in order to meet mass transport demands of the encapsulated cells. Fibroblast growth factor-1 (FGF-1) is a potent angiogenic factor with optimal effect occurring when it is delivered in a sustained manner. In this paper, a technique is described for the generation of multilayered alginate microcapsules with an outer alginate layer that can be used for the delivery of FGF-1. The influence of alginate concentration and composition (high mannuronic acid (M) or guluronic acid (G) content) on outer layer size and stability, protein encapsulation efficiency, and release kinetics was investigated. The technique results in a stable outer layer of alginate with a mean thickness between 113-164 µm, increasing with alginate concentration and G-content. The outer layer was able to encapsulate and release FGF-1 for up to thirty days, with 1.25% of high G alginate displaying the most sustained release. The released FGF-1 retained its biologic activity in the presence of heparin, and the addition of the outer layer did not alter the permselectivity of the PLO coat. This technique could be used to generate encapsulation systems that deliver proteins to stimulate local neovascularization around encapsulated islets.

show abstract

Cyotomedical therapy for insulinopenic diabetes using microencapsulated pancreatic β cell lines

Cited by 20 publications

References 48 publications

Inner Ear Therapy for Neural Preservation

Inner Ear Therapy for Neural Preservation

Methods for Photocrosslinking Alginate Hydrogel Scaffolds with High Cell Viability

Synthesis of multilayered alginate microcapsules for the sustained release of fibroblast growth factor‐1

Contact Info

Product

Resources

About